APOBEC3 enzymes mediate efficacy of cisplatin and are epistatic with base excision repair and mismatch repair in platinum response.

NAR Cancer
Kayla L ConnerSteve M Patrick

Abstract

Identifying the mechanisms mediating cisplatin response is essential for improving patient response. Previous research has identified base excision repair (BER) and mismatch repair (MMR) activity in sensitizing cells to cisplatin. Cisplatin forms DNA adducts including interstrand cross-links (ICLs) that distort the DNA helix, forcing adjacent cytosines to become extrahelical. These extrahelical cytosines provide a substrate for cytosine deaminases. Herein, we show that APOBEC3 (A3) enzymes are capable of deaminating the extrahelical cytosines to uracils and sensitizing breast cancer cells to cisplatin. Knockdown of A3s results in resistance to cisplatin and induction of A3 expression in cells with low A3 expression increases sensitivity to cisplatin. We show that the actions of A3s are epistatic with BER and MMR. We propose that A3-induced cytosine deamination to uracil at cisplatin ICLs results in repair of uracils by BER, which blocks ICL DNA repair and enhances cisplatin efficacy and improves breast cancer outcomes.

References

May 3, 2003·American Journal of Surgery·Vincent J PicozziL William Traverso
Jun 18, 2003·Cell·Reuben S HarrisMichael H Malim
Feb 6, 2004·Nature Reviews. Drug Discovery·Joanne GrahamPeter Kirkpatrick
Mar 25, 2005·Nature Reviews. Drug Discovery·Dong Wang, Stephen J Lippard
Apr 13, 2005·Current Biology : CB·James A DutkoM Joan Curcio
Jul 8, 2005·Proceedings of the National Academy of Sciences of the United States of America·April J SchumacherReuben S Harris
May 2, 2006·The Journal of Biological Chemistry·Mark D Stenglein, Reuben S Harris
May 27, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marianne BonvinJobst Greeve
Apr 19, 2007·Nucleic Acids Research·Masanobu KinomotoKenzo Tokunaga
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel P SilverJudy E Garber
Jul 31, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V J PicozziUNKNOWN American College of Surgeons Oncology Group
Oct 20, 2010·International Journal of Molecular Sciences·Hui ChenZuo-Jiong Gong
Mar 2, 2011·The Journal of Biological Chemistry·Anbarasi KothandapaniSteve M Patrick
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
May 23, 2012·Cell·Serena Nik-ZainalUNKNOWN Breast Cancer Working Group of the International Cancer Genome Consortium
Jun 23, 2012·Nature·Philip J StephensMichael R Stratton
Sep 14, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Harshini V MehtaChioma M Okeoma
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Feb 8, 2013·Nature·Michael B BurnsReuben S Harris
Jun 14, 2013·Nucleic Acids Research·Anbarasi KothandapaniSteve M Patrick
Jul 16, 2013·Nature Genetics·Steven A RobertsDmitry A Gordenin
Feb 22, 2014·Annual Review of Immunology·William M SchneiderCharles M Rice
Feb 22, 2014·Science·Julie LuciforaUlrike Protzer
Mar 14, 2014·Redox Biology·Benjamin M GyoriMarie-Veronique Clement
Aug 27, 2014·Cytokine & Growth Factor Reviews·Fan-ching Lin, Howard A Young
Aug 19, 2015·Journal of Molecular Biology·Sachini U SiriwardenaAshok S Bhagwat
Oct 1, 2015·Cancer Research·Brandon LeonardReuben S Harris

❮ Previous
Next ❯

Methods Mentioned

BETA
deamination
transfection
transfections
electrophoresis
deaminate

Software Mentioned

ImageJ
RStudio : Integrated Development for R
R
SigmaPlot
OpenComet

Related Concepts